InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.011 -0.032 (-74.42%)+
Announcement
Release
31 Jul 2026 3:03PM
Price at Release
$0.043
Full Release
download
Summary
Chimeric Therapeutics Limited, a leader in cell therapy, reported on its financial and operational activities for the quarter ending June 30, 2026. The company had $0.80 million in cash, a decrease from the prior quarter, with significant cash outflows attributed to operating activities, primarily for staff costs and research and development. Despite financial challenges, Chimeric announced positive interim results from its Phase 1/2 trial of CHM CDH17, a CAR T cell therapy, which showed promising clinical outcomes. The company received additional funding commitments and is actively exploring strategic options to enhance asset value. These efforts include strategic partnerships, funding, and possible mergers or asset sales.
Key Points
  • Chimeric Therapeutics Limited is focused on developing cell therapies for cancer treatment.
  • The Quarterly Activities Report includes an Appendix 4C Cash Flow Report.
  • As of June 30, 2026, Chimeric had $0.80 million in cash, down from $1.75 million at the end of the previous quarter.
  • Net cash outflow from operating activities for the quarter was $3.53 million.
  • The company reported positive interim data from its Phase 1/2 CHM CDH17 trial.
  • Chimeric received additional funding commitments of $4.0 million under a convertible note facility.
  • The company secured a $1.62 million R&D Advance from Endpoints Capital.
  • Chimeric continues to explore strategic partnerships and funding opportunities.
  • Chimeric's strategic review aims to maximize the value of its assets through various potential transactions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.